Regulating High Mannose Fab Glycoforms via Glucose Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody production methods struggle to regulate and maintain desired glycosylation patterns, particularly in the Fab region, which affects the therapeutic and diagnostic properties of antibodies, with existing methods failing to effectively control the relative content of high mannose glycoforms, leading to inconsistent pharmacokinetics and bioavailability.
Innovation Solution
Optimizing the concentration of glucose in the culture medium during the production phase of monoclonal antibody fermentation to regulate the relative content of high mannose Fab glycoforms, ensuring that no more than 20% of Fab regions have an N-linked high mannose glycan, thereby influencing the glycosylation profile and improving bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional monoclonal antibody production methods are used, then antibody production is achieved, but the glycosylation pattern in the Fab region cannot be regulated, leading to inconsistent high mannose glycoform content
Solution Approach 1:
The patent applies parameter changes by systematically optimizing glucose concentration in the culture medium during different production phases. By adjusting this chemical parameter, the method achieves precise control over Fab region glycosylation patterns, specifically reducing high mannose glycoform content to 20% or less while maintaining consistent glycosylation across batches.
2Reliability
If high mannose glycoforms are present in Fab regions, then antibody production is achieved, but clearance rate increases and bioavailability decreases
Solution Approach 1:
The patent applies preliminary action by controlling glucose concentration during the production phase to preemptively shape the glycosylation pattern. This preliminary control during manufacturing ensures that high mannose glycoforms are minimized (20% or less), which subsequently reduces clearance rate and improves bioavailability during the antibody's pharmacokinetic profile.
3Manufacturing precision
If glucose concentration is optimized during production phase, then high mannose glycoform content is reduced to 20% or less, but requires precise control of culture conditions
Solution Approach 1:
The patent applies feedback by monitoring and adjusting glucose concentration during the production phase based on its established relationship with high mannose glycoform content. This feedback mechanism enables precise control of glycosylation patterns, ensuring high mannose forms remain at 20% or less while providing a systematic approach to managing culture conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the rate of antibody clearance and enhances bioavailability by maintaining a consistent pharmacological profile, improving the therapeutic efficacy and diagnostic performance of monoclonal antibodies.
Implementation Method 1
The key therapeutic or diagnostic properties of monoclonal antibodies are strongly related to the post-translational process of glycosylation
Implementation Method 2
during the production phase of monoclonal antibody fermentation
Data Source
AI summary
The present invention relates to glycosylation patterns at the Fab portion of a monoclonal antibody and methods for the regulation during culture of a microorganism expressing a monoclonal antibody with regulated content of high mannose Fab glycoforms.